You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股异动 | 药明生物(2269.HK)涨近4%领涨蓝筹股 终止由历史高位九连跌
格隆汇 09-11 15:00
格隆汇9月11日丨本周一起正式“染蓝”的药明生物(2269.HK)终止由历史高位九连跌,现涨近4%领涨恒指成份股,报185.1港元。美银证券发研报指,疫情下药明生物上半年业绩仍带来惊喜,保持强劲增长,产能利用率提高推动利润提升。该行将2020至2022年每股盈利预测提升至1.37、2.07及3.04元人民币,目标价由116港元调高至200港元,并重申“买入”评级。瑞银发表报告指,虽然业务环境艰难,但药明生物(2269.HK)在今年上半年仍签署了38个新项目(早前指引为20个),令集团上半年收入及纯利表现均优于预期。该行上调药明生物股份目标价,由167港元升至227港元,维持“买入”评级

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account